Valeria A. Koltyugina

Valeria A. Koltyugina

Auto-generated profile, based on publicly available information

Valeria A. Koltyugina

Novosibirsk National Research State University, Novosibirsk, Russia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2025 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
NLNatalya Lozhkina
Natalya Lozhkina
NDN. P. Dobrovolskaya
N. P. Dobrovolskaya
SASergey Artemenko
Sergey Artemenko
MSM. V. Shipunov
M. V. Shipunov
ASA. D. Sharonin
A. D. Sharonin
MVM. I. Voyevoda
M. I. Voyevoda
Aim. To compare efficacy and safety of inclisiran, evolocumab and alirocumab in patients with high, very high and extreme cardiovascular risk (according to data from the Federal Research Center for Cardiology and Microbiology, Novosibirsk).Material and methods. This prospective two-year observational comparative included 53 patients (43 men and 10 women) with an average age of 61,2±4,7 years. They were treated with alirocumab at a dose of 75 mg (n=9) and 150 mg (n=25), evolocumab 140 mg (n=10), and inclisiran (n=9). Two patients were diagnosed with definite familial hypercholesterolemia according to DLCN criteria, while five patients had a myocardial infarction. Lipid profile, transaminase, creatinine, and glucose levels were assessed after 3, 6, 12, and 24 months. The primary efficacy endpoint was achievement of target low-density lipoprotein (LDL) values. The secondary efficacy endpoint was recurrent cardiovascular events (myocardial infarction, stroke, urgent coronary and non-coronary artery revascularization, critical ischemia and lower extremity amputation). New cases of diabetes and atrial fibrillation were also monitored. Safety was assessed based on clinical data and laboratory parameters, such as transaminase, total bilirubin, creatinine and blood glucose levels. The follow-up period ranged from 6 months to 2 years.Results. Target LDL cholesterol levels for extreme cardiovascular risk were achieved in 21 of 32 patients, and for very high and high risk levels — in 16 of 21 patients. The average LDL level decreased from 3,71 to 1,47 mmol/L during the period of lipid-lowering therapy, while no differences were found between the treatment subgroups. During the two-year follow-up, no endpoints were observed in the study patients. High compliance and good tolerability of all types of treatment with no adverse reactions, including local ones, were noted. None of the patients discontinued therapy.Conclusion. This single-center study showed that therapy with a PCSK9 inhibitor and inclisiran was well tolerated, and LDL-C reduction was similar to that observed in randomized, placebo-controlled trials.

1 January 2025 in Bulletin of Medical Science
Verified
Journal Article
Open access
NONovosibirsk
Novosibirsk
NLNatalya Lozhkina
Natalya Lozhkina
Andrey Igorevich MurzinAndrey Igorevich Murzin
Andrey Igorevich Murzin
VKValeria A. Koltyugina
Valeria A. Koltyugina
KKKonstantin A. Kuznetsov
Konstantin A. Kuznetsov
Developed by the European Society of Cardiology (ESC) Peripheral Arterial and Aortic Disease Task Force in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS), with special input from the ESC European Association for Rare Multisystemic Vascular Diseases (VASCERN) and the European Society for Vascular Medicine (ESVM). Lucia Mazzolai, Gisela Teixido-Tura, Stefano Lanzi, Vinko Boc, Eduardo Bossone, Marianne Brodmann, Alessandra Bura-Rivière, Julie De Backer, Sebastien Deglise, Alessandro Della Corte, Christian Heiss, Marta Kałużna-Oleksy, Donata Kurpas, Carmel M McEniery, Tristan Mirault, Agnes A Pasquet, Alex Pitcher, Hannah A I Schaubroeck, Oliver Schlager, Per Anton Sirnes, Muriel G Sprynger, Eugenio Stabile, Françoise Steinbach, Matthias Thielmann, Roland R J van Kimmenade, Maarit Venermo, Jose F Rodriguez-Palomares, ESC Scientific Document Group. Full text of the guideline is published: European Heart Journal, Volume 45, Issue 36, September 21, 2024, Pages 3538-3700, https://doi.org/10.1093/eurheartj/ehae179

1 January 2026 in Bulletin of Medical Science
Verified
Journal Article
Open access
VKValeria A. Koltyugina
Valeria A. Koltyugina
NLNatalya Lozhkina
Natalya Lozhkina
AGAsal Ghafari
Asal Ghafari
This review examines current clinical guidelines for the diagnosis of pulmonary embolism (PE) and presents an analysis of the current scientific literature. A diagnostic algorithm is synthesized based on consensus approaches. The review uses data from publications in PubMed and Google Scholar, covering a 5-year period.

1 January 2024 in Bulletin of Medical Science
Verified
Journal Article
Open access
NUNovosibirsk National Research State University
Novosibirsk National Research State University
VKValeria A. Koltyugina
Valeria A. Koltyugina
NLNatalya Lozhkina
Natalya Lozhkina
The article deals with the treatment of dyslipidemia with HMG-CoA reductase inhibitors as well as non-statin lipid lowering drugs. Several lipid-lowering drugs have emerged in recent decades: bile acid sequestrants, fibrates, nicotinic acid, ezetimibe, bempedoic acid, volanesoren, evinacumab, PCSK 9 inhibitors evolocumab and alirocumab, and inclisiran. Although statins remain the gold standard of treatment, PCSK9-targeted therapy will play an increasingly important role in the correction of dyslipidemia. The review utilized information on the topic from publications based on PubMed and Google Scholar databases, depth of coverage 5 years.